Detailed Narrative
Q2 FY26 Performance Overview and Turnaround
Indoco Remedies reported a strong Q2 FY26, marking the first quarter of an uptick in performance after a challenging previous year. Consolidated net revenues grew 9.5% YoY to ₹471.8 crores, with standalone net revenues increasing 8.8% YoY to ₹429.3 crores. The company achieved a significant QoQ improvement in standalone EBITDA margin, rising to 12.4% (₹53.4 crores) from 3.8% (₹14.8 crores) in Q1 FY26, demonstrating progress in cost control and efficiency.
Regulatory and Product Pipeline Updates
The US FDA completed an inspection of the API manufacturing facility at Patalganga with zero observations, a positive regulatory outcome. Furthermore, the company received tentative US FDA approval for Canagliflozin in November 2025, a product filed four years prior, with sales expected to commence in 2028. In the India market, Indoco launched six new products across anti-infective, respiratory, and dental segments, including Vepazil 250/500 and Tuspel AA.
International Business Performance and Outlook
International formulation revenues grew 21.5% YoY to ₹153.3 crores. US business revenue saw a 36% YoY increase to ₹33.6 crores. While Europe revenue declined 8.7% YoY to ₹54.7 crores due to distribution challenges and diversion of production to the US, management expects a double-digit growth from Q3 FY26 onwards, targeting ₹300 crores in annual revenue by FY27. The company is also focusing on derisking its US strategy by leveraging CMOs rather than upfront investments.
Subsidiary Performance and Strategy
Subsidiaries FPP and Warren Remedies (WRPL) reported a combined loss of ₹23 crores this quarter. FPP is expected to break even in a couple of quarters, while WRPL, which includes OTC and API intermediates, is projected to continue bleeding for another two quarters, with EBITDA breakeven anticipated by FY27. The OTC business, though initially margin-draining due to advertising, is seen as a strategic investment for brand building and market expansion.
Capital Allocation and Debt Management
The company has completed heavy capex investments over the last two years and anticipates no further significant capex for the next few years, focusing instead on maintenance capex of ₹50-70 crores annually. Management acknowledged the rising debt profile and increased interest costs, committing to repay ₹52 crores in H2 FY26 and ₹140 crores in FY27. Operating cash flow in Q2 FY26 was almost equal to the entire last year's generation, supporting debt reduction efforts.
Revised Revenue Targets and R&D Focus
The ambitious ₹5,000 crore revenue target for 2027 has been revised, now expected to be realized approximately 18 months beyond 2027. A new target of around ₹3,500 crores in revenue is set for three years from now (FY29). R&D spend, currently hovering at 5% of sales, is targeted to be reduced to 4% in FY27, with a strategic focus on vertically integrated API products and volume builders rather than high-risk Para IV opportunities.